T
Thomas J. Lynch
Researcher at Yale Cancer Center
Publications - 37
Citations - 11860
Thomas J. Lynch is an academic researcher from Yale Cancer Center. The author has contributed to research in topics: Lung cancer & Bevacizumab. The author has an hindex of 21, co-authored 37 publications receiving 10478 citations. Previous affiliations of Thomas J. Lynch include Yale University.
Papers
More filters
Journal ArticleDOI
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Jennifer S. Temel,Joseph A. Greer,Alona Muzikansky,Emily R. Gallagher,Sonal Admane,Vicki A. Jackson,Constance Dahlin,Craig D. Blinderman,Juliet Jacobsen,William F. Pirl,J. Andrew Billings,Thomas J. Lynch +11 more
TL;DR: Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood and, as compared with patients receiving standard care, patients received less aggressive care at the end of life but longer survival.
Journal ArticleDOI
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist,Belinda A. Waltman,Dora Dias-Santagata,Subba R. Digumarthy,Alexa B. Turke,Panos Fidias,Kristin Bergethon,Alice T. Shaw,Scott N. Gettinger,Arjola K. Cosper,Sara Akhavanfard,Rebecca S. Heist,Jennifer S. Temel,James G. Christensen,John C. Wain,Thomas J. Lynch,Kathy Vernovsky,Eugene J. Mark,Michael Lanuti,A. John Iafrate,Mari Mino-Kenudson,Jeffrey A. Engelman +21 more
TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.
Journal ArticleDOI
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Joel W. Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck +10 more
TL;DR: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipil optimumab in NSCLC.
Journal ArticleDOI
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Martin Reck,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Haolan Lu,J.-M. Cuillerot,Thomas J. Lynch +9 more
TL;DR: The results of this phase 2 study suggest further investigation of ipilimumab in ED-SCLC, and highlight the need for further investigation into the anti-CTLA4 monoclonal antibody.
Journal ArticleDOI
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch,Taral Patel,Luke Dreisbach,Michael McCleod,William J. Heim,Robert C. Hermann,Eugene Henry Paschold,Nicholas Iannotti,Shaker R. Dakhil,Steven Gorton,Virginie Pautret,Martin R. Weber,Donald Woytowitz +12 more
TL;DR: The addition of cetuximab to TC did not significantly improve the primary end point, PFS-IRRC, and there was significant improvement in ORR by IRRC.